VITA 34 AG (0NLV.L)

4.4000 -0.5800 (-11.65%) At close: 05:27PM BST

VITA 34 AG

Deutscher Platz 5a
Leipzig 04103
Germany
49 341 48792 40
https://www.vita34.de

Sector(s): 
Industry: 
Full-time employees: 745

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Jakub Julian Baran	Chairman of the Management Board & CEO	N/A	N/A	N/A
Mr. Tomasz Franciszek Baran	Vice President of the Management Board & Chief Commercial Officer	N/A	N/A	N/A
Santiago Luengo	Managing Director of Secuvita	N/A	N/A	N/A

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

VITA 34 AG engages in the collection, processing, cryopreservation, and storage of stem cells from umbilical cord blood and tissue and postnatal tissue in Germany, Poland, Portugal, and internationally. It operates through Subgroup Vita 34 And Subgroup PBKM segments. The company produces and develops advanced therapies products for third parties. It also develops products and drugs based on cells, tissues, and blood for medical applications; and produces and manufactures viral vectors and CAR-T cells. In addition, the company provides biobanking services, such as freezing sperm and storage of adipose tissue and the isolation of cells from the stored materials. VITA 34 AG was founded in 1997 and is based in Leipzig, Germany.

Corporate governance

VITA 34 AG’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.